Skip to content

Using Healthcare Financing and Digital Technology to Improve Hypertension Prevention and Control in Tanzania

STOP NCDs: Scaling up Evidence-based Health System Interventions Through the Use of Sustainable Healthcare Financing and Digital technOlogy Platforms to Improve Non- Communicable Disease Prevention and Control in Tanzania

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06379750
Enrollment
1320
Registered
2024-04-23
Start date
2026-10-01
Completion date
2028-03-01
Last updated
2026-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Hypertension

Keywords

hypertension, diabetes, NCD management, NCD prevention, mHealth, healthcare financing

Brief summary

The aim of our proposed program is to develop and implement a multilevel, multicomponent and health-financing intervention that will facilitate the scale up of evidence-based strategies to improve non-communicable diseases prevention, detection and control in Tanzania. The investigators will accomplish this by: 1) adapting two intervention components that are candidates for inclusion in a highly effective optimized strategy (called STOP-NCDs) and; (b) Assess their individual and combined effectiveness and 2) conducting a robust, mixed-methods evaluation of the implementation process and assess factors that may influence implementation and sustainability for delivering and scaling the optimized STOP-NCDs strategy. The investigators will select and/or adapt intervention components making up the optimized STOP-NCDs strategy. Using a hybrid clinical-effectiveness implementation design, the investigators will conduct a study in 2 sequential phases: 1) A clinical-effectiveness phase in which the investigators evaluate the effect of our combined strategies (task-sharing and WelTel) versus Usual Care, on rates of systolic BP reduction at 12 months; as well as other secondary outcomes including diagnosis and treatment of diabetes and, patient knowledge of CVD risks and prevention, and, other features of health provider NCD prevention activities. 2) A post-implementation phase in which the investigators use the RE-AIM framework to evaluate changes in the adoption and maintenance of our combined strategies in participating iCHF health facilities across Kilimanjaro region. The investigators will use the WelTel communication and Patient Management platform for to deliver culturally and contextually appropriate evidence-based text messaging to patients. It allows for quality improvement and is a unique tool for our program to scaling low-cost interventions that provide capabilities for tracking of health system service uptake, quality-metrics at health facilities, drug stock-out management, and patient-centered behavioral health interventions. Deployment of WelTel will allow for integration of NCD prevention targeted health services to all adult iCHF members across differing life stages and NCD risk and have a significant impact on increasing quality of care and sustainability of health financing and performance-based incentives through improved prescribing, patient engagement, medication adherence and healthy behaviour change.

Interventions

OTHERNurse-delivered care using WelTel check-ins and BCC SMS

Nurse-delivered HTN, DM and CVD risk assessment, diagnosis and Management (through NIMONCD) using WelTel check-ins and BCC SMS

OTHERCommunity-based peer-support model

Community-based peer- support model using Weltel check-ins and BCC SMS and facilitated group self monitoring

Sponsors

Dr. Karen Yeates
Lead SponsorOTHER
Kilimanjaro Clinical Research Institute
CollaboratorOTHER
Muhimbili University of Health and Allied Sciences
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* All adults with uncontrolled HTN who receive care through iCHF membership and are able to provide informed consent.

Exclusion criteria

* Adults with controlled HTN or those without a diagnosis of HTN * Unable or unwilling to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Systolic blood pressure12 monthsChange in systolic blood pressure from baseline to last follow-up visit

Secondary

MeasureTime frameDescription
Blood pressure control12 monthsProportion of participants with controlled blood pressure (\<140 mm Hg for systolic and \<90 mm Hg for diastolic) at the last follow-up visit

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 25, 2026